Graves' Disease clinical trials at UCSF

2 in progress, 1 open to eligible people

Graves' disease is when the immune system makes the thyroid too active and causes health problems. UCSF is testing a new medicine in adults to measure safety, side effects, and if it lowers thyroid hormones. UCSF is also running other studies that look at treatments and blood tests.

Showing trials for

  • IMVT-1402 as Treatment for Adult Participants With Graves' Disease

    open to eligible people ages 18-75

    This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.

    San Francisco, California and other locations

  • IMVT-1402 in Adult Participants With Graves' Disease (GD)

    Sorry, accepting new patients by invitation only

    This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

    San Francisco, California and other locations

Last updated: